Tin tức & Cập nhật

CHK1 inhibition with prexasertib appears to have durable activity in some patients with recurrent ovarian cancer regardless of clinical characteristics, BRCA status, or prior therapies, according to the results of a phase II trial.

In the second interim overall survival (OS) analysis of the phase III TROPiCS-02 study, sacituzumab govitecan (SG) – a first-in-class Trop-2*-directed antibody-drug conjugate approved for triple-negative metastatic breast cancer (mBC) with ≥2 prior therapies (≥1 in the metastatic setting) – conferred an OS benefit for pretreated HR+/HER2– mBC, compared with treatment of physician’s choice (TPC**).

Neurodevelopment appears to be significantly delayed at up to 4 years of age in boys who are born to mothers with gestational diabetes mellitus (GDM), reports a recent study.

Prepregnancy intakes of total fat, unsaturated fat, and monounsaturated fatty acid (MUFA) do not appear to contribute to hypertensive disorders of pregnancy (HDP), but trans fatty acid (TFA) shows a positive association with HDP, reports a study.

Maintenance therapy with the PARP* inhibitor niraparib led to a sustained and durable progression-free survival (PFS), regardless of biomarker status, in patients with primary advanced ovarian cancer who responded to platinum-based chemotherapy, an updated analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial has shown.